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Abstract  
A method of quantitative determination of SS-68 derivative of indole in rabbit blood plasma by 
high performance liquid chromatography with tandem mass spectrometric detector (HPLC-
MS/MS). Conducted pharmacokinetic studies SS-68 in the body of rabbits. Set the main 
pharmacokinetic parameters of the substance that allow you to optimize the future use of it’s as a 
potential drug in cardiology practice.  
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Introduction 
In previously studies was shown that compound 
SS-68 has a preventive and stopping action in case of 
cardio-neurogenesis rhythm disorders of heart 
outweighing the activity of number traditional and 
modern antiarrhythmic drugs [1-8]. High 
antiarrhythmic efficacy of SS-68 is connected with 
the blocking of ion currents (in maximal to 
acetylcholine-depended K
+
 current, Ca
2+ 
L-type 
current and fast K
+ 
current of the detained 
straightening), choline- and adrenoreceprores of 
cardiomiocites and neurons [8-11]. 
In conditions of intact and ischemized 
myocardium SS-68 increases a volume rate of 
coronary blood flow, makes an oxygen reserve in 
myocardium, decreases a blood pressure, slows a 
heartbeat, increases collateral blood circulation in 
ischemic focus, decreases a oxygen consumption by 
myocardium  [12-14]. Antianginal SS-68 properties 
are due to blocking of pacemaker cells If- [15] and 
β1-adrenoreceptors. Coronary- and vasodelatating 
(peripheral arteries) activity of SS-68 is combined 
with activating at ATP-sensitive K
+
 canals of smooth 
muscle cells (SMC) of coronal vessels in the first 
case, and with the increasing of a total exiting K
+
 
current, entailing the hyperpolarization activated 
SMC arteries, which leads to the blockade of Ca
2+
- 
potential controlled channels and relaxation of SMC 
[6]. 
In addition, SS-68 has pleiotropic properties: a 
bronchodilator (due to β2-adrenomimetic action), 
antithrombotic (antiplatelet) and anti-inflammatory 
[6, 9] actions. 
The above data indicate the feasibility of further 
preclinical study SS-68 to create on its basis drugs 
having antiarrhythmic and antianginal effects. 
Experimental part 
Reagents used in this study are the follows: 
fabomotizole (Sigma), formic acid (Panreac), 
ammonium acetate (Panreac), methanol (Merk) 
acetonitrile for gradient chromatography (Merk), 
water purified and deionized with “Gene Pure” 
system (Thermo Scientific, USA). The method of 
synthesis of compounds SS-68 developed and the 
necessary quantity acquired within the framework of 
the state task of the Ministry of education and science 
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of the Russian Federation No. 4.129.2014 in the 
Department of chemistry of natural and 
macromolecular compounds, faculty of chemistry of 
southern Federal University. 
The definition of SS-68 in the blood plasma of 
rabbits was carried out with a liquid chromatograph 
UltiMate 3000 LC (Thermo Fisher Scientific, USA) 
equipped with a thermostated automatic dispenser, 
vacuum degasser, gradient pump, and column 
thermostat. Detection of the analyte was carried out 
with a mass-spectrometer 
Velos Pro (Thermo Scientific, USA) under 
ionization in the heated electrospray (H-ESI-II). 
 Instruments and UHPLC–MS/MS Conditions 
Chromatographic separation was performed on a 
column size of 150 × 3.0 mm, filled by reversed-
phase sorbent Eclipce  Zorbax XDB C18 with 
particle size 3.0 mm with guard column Zorbax XDB 
C18 Eclipce of 12.5×3.0 mm with a particle size of 
5.0 µm at a temperature of 40 °C in the mode of 
linear gradient of eluent at a flow rate of 0.4 ml/min 
by the following program:  
– the stage of separation:  eluent A (5 mM 
Ammonium acetate + 0.1% formic acid) to 55% → 
45%; eluent B (acetonitrile) to 45% → 55% in 4 
minutes; 
- the washing step:  eluent A (5 mM Ammonium 
acetate + 0.1% formic acid) to 45%; eluent B 
(acetonitrile) – 55% – 0,5 minutes; 
– stage equilibration: eluent A (5 mM 
Ammonium acetate + 0.1% formic acid) – 55%; 
eluent B (acetonitrile) to 45% in 2 minutes. 
The volume of injected sample was 5 µl. 
Approximate retention times under these conditions: 
SS-68 – about 3.7 min; internal standard 
(fabomotizole) – about 2.1 min. Injection time of 7.0 
min. Ionization was performed with H-ESI in the 
positive -ion mode. Scanning was performed by 
selectively ion monitoring (SIM). The precursor-
product ion transitions for SS-68 – 305,26→208,0, 
internal standard (fabomotizole) – 307,41→114,0. 
The collision energy for SS-68 – 43, for the internal 
standard (fabomotizole) – 30. The voltage at the 
source is 3000 V. The source temperature 300 °C. 
The temperature of the capillary 350°C. The sheath 
gas pressure 60 Arb. Aux gas pressure of 20 Arb. 
Sample preparation. 
In accordance with modern requirements for 
bioanalytical methods [16, 17, 18] prepared standard 
solutions with different concentrations. Preparation 
of solutions SS-68 included several stages. The first 
stage was preparing the stock solution SS-68 in 
methanol with a concentration 0,080 %. In a second 
step by a series of dilutions prepared solutions SS-68 
in methanol to be added to the standard solutions and 
solutions of quality control with a concentration of 
0,00080 %, 0,0000080%. Solution internal standard 
(fabomotizole) used on one level, the concentration 
in methanol 0,0008 % to add to the subjects, standard 
and test solutions. 
Solutions to create a calibration curve prepared 
in seven concentrations. For this,    100 µl of plasma 
was placed in 1.5 ml Eppendorf , then added aliquots 
of stock solutions and 100 µl of internal standard, 
mixed, added 100 µl of acetonitrile, mixed. Then we 
carried out the extraction of the analyte by vortex for 
3 minutes. After extracting the samples were 
centrifuged at 13000 rpm and a temperature of 4 ºC 
for 25 minutes. The supernatant was decanted and 
analyzed. Thus were prepared solutions of 14 with 
seven concentrations – 8,02 ng; 80,2 ng; 802,0 ng; 
1604,0 ng; 2406,0 ng; 4010,0 ng;  and 8020,0 ng in 1 
ml of plasma of rabbits. Each level was prepared and 
analyzed twice. 
Solutions quality control (QC)  were prepared 
similarly solutions to create a calibration curve at 
four levels of concentrations – 8,02 ng (lower limit of 
quantification – LLOQ), 80,2 ng (lower quality 
control – LQC), 1604,0 ng (middle quality control – 
MQC) and 4010,0 ng (upper quality control – UQC) 
in 1 ml of plasma of rabbits. Thus, we conducted a 
validation of the results obtained during the research. 
The analytical range of determination was from 8,02 
up to 8020,0 ng in 1 ml of rabbit plasma. 
The regulations of the pharmacokinetics studies. 
To study the pharmacokinetics of SS-68 12 
rabbits were pre-catheterized in the right ear vein so 
blood samples at all time points were taken from the 
same animals throughout the experiment. 12 hours 
before the start of the experiment the animals were 
deprived of feed, leaving free access to water. On the 
third day after catheterization were administered the 
test substance. Intravenous dosing the test substance 
was administered bolus of 6 rabbits in the ear vein in 
a solution of 22.0 mg/ml in water for injection at a 
dose of 2.2 mg/kg. Blood was sampled through a 
catheter in a volume of 0.3 ml in polypropylene tubes 
containing 20 µl of 5 % EDTA before using|, 5, 15, 
30, 60, 120, 240, 480 and 1440 minutes after 
injection. When intragastric dosing of the substance 
is introduced using a probe in a solution of 22.0 
mg/ml in water for injection at a dose of 22.0 mg/kg. 
Blood was sampled through a catheter in a volume of 
0.3 ml in polypropylene tubes containing 20 µl of 5% 
EDTA prior to insertion, using 15, 30, 60, 120, 240, 
480 and 1440 minutes after injection. Blood plasma 
was separated by centrifugation at 5600 g for 10 min 
and stored until analysis at -70 ºC. 
To determine the concentration used validated 
the method of determining the SS-68 in the blood 
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plasma of rabbits in accordance with the Guidance on 
the examination of drugs under editorship of  
professor A. N. Mironov, volume I [16], as well as 
guidance for validation of  bioanalytical methods 
FDA [17] and EMA [18], with the following 
characteristics: selectivity (specificity), linearity, 
accuracy and precision (intra-day and inter-day), 
quantification limit,  robustness, the matrix effect and 
the carry-over. 
Main pharmacokinetic parameters were 
calculated in accordance with the guidelines for 
preclinical studies of pharmaceuticals under the 
editorship of professor A. N. Mironov [19] in 
Microsoft Office Excel 2010 on the basis of the 
experimentally obtained data was calculated the 
pharmacokinetic parameters. 
Dropping out results of the animals at each time 
point were detected by Grubbs statistical test [20]. 
This method showed good and accurate results [21, 
22].   We calculated the arithmetic mean values and 
coefficient of variation (CV) for 6 animals. 
Аaveraged pharmacokinetic curves and calculate 
the main pharmacokinetic parameters were 
constructed on the basis of the data obtained. 
Calculations made no model method, statistical 
analysis was performed in Excel. 
Results and discussion. 
Studies have shown that the SS-68 was rapidly 
absorbed from the gastrointestinal tract (mean time of 
absorption (MAT) - 36.3 min) and enters the 
systemic circulation within 15 minutes after 
administration. The maximum concentration (Cmax) 
was 296.8 ng / mL of plasma. Then a rapid decrease 
of the concentration, the presence of characteristic  
plateau  after 24 hours study approaching the 
threshold determination method. Reduced bore 
biexponential character, suggesting a rapid 
distribution of the first phase is replaced by a slower 
elimination phase. The presence of a plateau on the 
concentration-time curve shows several phases of 
distribution, which occur in sequence. Phase 
distribution and elimination for intravenous and 
intragastric administration at different times. This is 
due to the different time to achieve Cmax. For two 
hours study SS-68 decreased the concentration of 
only 1.6 times (determined by the second hour 179,6 
(CV – 17,6%) ng / ml plasma). This indicates that the 
SS-68 undergoes slow elimination in rabbits body. 
The averaged pharmacokinetic curves with a 
graphical display of the CV for each point shown in 
Figure 1. 
 
 
Figure 1. Mean plasma concentration-time curve of SS-68 (n = 6). 
 
Main pharmacokinetic parameters (Table. 1) 
show the average half-life (T1/2 = 2.5 h 
intragastrically and T1/2  = 3.9 h intravenously) and 
the average retention time in the organism (MRT (0-t) 
= 5.5 h intragastrically, MRT (0-t) = 4.9 h 
intravenously). The areas under the concentration-
time curve (AUC (0-1440) = 116,128.1 ng/mL×min in 
intragastrically, AUC (0-1440) = 69686.3 ng/mL×min 
intravenously). The magnitude of the stationary 
distribution volume (Vss) is equal to 10.8 l/ kg, far 
more than the extracellular fluid volume in the body 
of rabbits, indicating that high ability of the drug 
distributed and accumulate in tissues. Related to this 
low value indicator systemic clearance  
(Cl = 0.032 l/h). 
The obtained pharmacokinetic parameters for 
different ways of doing showed that when 
administered intragastrically T1/2  = 2.5 h (151.7 min) 
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which is lower than by intravenous administration T1/ 
2 = 3.9 hours (235.9 min). The absolute 
bioavailability (fa) with intragastric administration 
was 16.6%. This fact is a certain rationale for the 
development of injectable form of the drug.  
Table. 1 
Mean pharmacokinetic parameters for SS-68 in the plasma 
rabbit (M±m; n = 6) 
Pharmacokinetic parameters 
Result 
intragastrically intravenously 
AUC(0-1440)
*
, 
(ng/mil)×min 
116128±34025 69686±3693 
AUMC(0-1440)
*
, 
(ng/mil)×min 2 
37656266±10882661 23754516±3278123 
MRT
*
(0-t), min 328,5±10,8 292,2±33,606 
Кel* , min-1 0,00490±0,00145 0,00297±0,00036 
T1/2
*
, min 151,7±48,9 235,9±27,1 
Cmax
*
, ng/ml 301,1±44,5 632,8±70,9 
Cmax iv /AUC (0-1440)
*
, min
-1
 0,00270±0,00056 0,00907±0,00068 
tmax
*
, min 17,5±6,1 - 
С1т
*
, l/h 0,032±0,002 - 
Vss
*
, l/kg 10,7±1,2 - 
fa
*
, % 16,6±4,5 - 
MAT
*
, min 36,3±10,3 - 
 
*Note:  AUC (0-1440) – the area under the concentration-time curve from 0 to the last sampling point (ng /ml)×min; AUMC 
(0-1440)  – derivative of the area under the concentration-time curve from 0 to the last sampling point (ng /ml)×min
2; MRT (0-t) – 
mean residence time of the substance in the body, min; Kel – elimination constant, min -1; T1/2 – half-life, min; Cmax – the 
maximum concentration, ng/ml; Cmax iv/AUC (0-1440) – absorption speed, min
-1; tmax – time to maximum concentration of mines; 
С1т – systemic clearance, l / h; Vss – steady volume of distribution, l / kg; fa – absolute bioavailability,%; MAT – С1т time, min. 
 
Conclusions. 
1. The studies of basic parameters SS-68 
pharmacokinetics allowed to develop a method for 
the quantitative determination of the substance in the 
blood plasma of rabbits. 
2. The pharmacokinetics SS-68 by intravenous 
and intragastric administration to rabbits. It is found 
that the drug is rapidly absorbed (MAT = 36,3 min) is 
well distributed in the tissues (Vss, = 10,8 l/kg) and 
has a T1/2 of 3.9 h (235.9 min) after intravenous 
dosing. It has a low absolute bioavailability (fa = 
16,6%), by the oral route. 
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